SequelSEC

Hepion Pharmaceuticals, Inc. HEPA

Pharmaceutical Preparations · CIK 0001583771 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2024-03-31
Operating income
-$40.42M
Fiscal year ended 2024-03-31
Free cash flow
Unavailable
Fiscal year ended 2024-03-31

Hepion Pharmaceuticals, Inc. (HEPA) reported revenue of $0 and net income of -$38.52M for the fiscal year ended 2024-03-31. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Hepion Pharmaceuticals, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Hepion Pharmaceuticals, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-03-31
Revenue$0
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$40.42M
Net income-$38.52M
Research & development$28.38M
Weighted-average diluted sharesUnavailable
Pretax income-$41.90M
Income tax expense-$3.38M
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$8.85M
Selling & marketingUnavailable

Balance

Hepion Pharmaceuticals, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-03-31
Cash & equivalentsUnavailable
Total assets$15.99M
Current assets$15.43M
Total liabilities$8.47M
Current liabilities$2.57M
Total equity incl. NCI$7.52M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$1.50M

Cash flow

Hepion Pharmaceuticals, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-03-31
Operating cash flow-$36.29M
Capital expendituresUnavailable
Investing cash flow-$14.30K
Financing cash flow$6.34M
Net change in cash-$29.89M
Stock-based compensation$115.33K
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$79.85K

Derived

Hepion Pharmaceuticals, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-03-31
Free cash flowUnavailable
Gross marginUnavailable
Operating marginUnavailable
FCF marginUnavailable
SBC / revenueUnavailable
Current ratio5.99x
Revenue YoY growthUnavailable
Net marginUnavailable
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open HEPA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-03-12View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-19View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.